焦磷酸钙晶体关节炎治疗的当前进展
Current advances in therapies for calcium pyrophosphate crystal arthritis.
作者信息
Sivera Francisca, Andrés Mariano, Pascual Eliseo
机构信息
aSección de Reumatología, Hospital General Universitario de Elda bSección de Reumatología, Hospital General Universitario de Alicante cDepartamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain *Francisca Sivera and Mariano Andrés equally contributed to the writing of this manuscript and share first authorship.
出版信息
Curr Opin Rheumatol. 2016 Mar;28(2):140-4. doi: 10.1097/BOR.0000000000000252.
PURPOSE OF REVIEW
Calcium pyrophosphate (CPP) crystal disease is a common rheumatologic disorder that has received limited attention from the scientific community. This review is aimed at summarizing current evidence for managing CPP disease (CPPD), focusing on recently reported advances.
RECENT FINDINGS
New data from case series indicate that interleukin-1β inhibitors can help patients with refractory forms of CPPD. Methotrexate, formerly a promising agent, failed to demonstrate benefits in a recent trial, but still merits consideration for some patients. No significant advances on crystal dissolution have been achieved to date. Proper characterization of the CPP crystal disease picture is needed, ruling out the possible coexistence of another persistent arthritis unrelated to the CPP deposition.
SUMMARY
Advances on CPP crystal dissolution and establishing definitions of the clinical spectrum of CPPD remain the main challenges for CPP crystal disease management.
综述目的
焦磷酸钙（CPP）晶体病是一种常见的风湿性疾病，但科学界对其关注有限。本综述旨在总结目前关于焦磷酸钙疾病（CPPD）管理的证据，重点关注最近报道的进展。
最新发现
病例系列的新数据表明，白细胞介素-1β抑制剂可帮助患有难治性CPPD的患者。甲氨蝶呤曾是一种有前景的药物，但在最近的一项试验中未能显示出益处，但仍值得一些患者考虑。迄今为止，在晶体溶解方面尚未取得重大进展。需要对焦磷酸钙晶体病情况进行适当的特征描述，排除可能与焦磷酸钙沉积无关的另一种持续性关节炎的共存。
总结
焦磷酸钙晶体溶解方面的进展以及确定CPPD临床谱的定义仍然是焦磷酸钙晶体病管理的主要挑战。
Zotero 插件